Results 61 to 70 of about 24,724 (196)

Pharmacokinetic Drug–Drug Interaction Potential of Oral Anticancer Drugs

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Drug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.
Fatimah Alhurayri   +10 more
wiley   +1 more source

Comparison of the effects of olsalazine and decitabine on the expression of CDH1 and uPA genes and cytotoxicity in MDA-MB-231 breast cancer cells

open access: yesResearch in Pharmaceutical Sciences, 2021
Background and purpose: Since DNA methyltransferase enzymes play a key role in DNA methylation, they can be used as a target to alter epigenetic changes and treat cancer.
Misagh Mohammadi Asl   +2 more
doaj   +1 more source

The nucleotidohydrolases DCTPP1 and dUTPase are involved in the cellular response to decitabine [PDF]

open access: yes, 2016
Decitabine (5-aza-2acute;-deoxycytidine, aza-dCyd) is an anticancer drug used clinically for the treatment of myelodysplastic syndromes and acute myeloid leukemia that can act as a DNA-demethylating or genotoxic agent in a dose-dependent manner.
Horváth, András   +4 more
core   +1 more source

Systemic anti‐cancer therapy associated with the occurrence of peripheral neurotoxicity and, specifically, peripheral neuropathy

open access: yesInternational Journal of Cancer, EarlyView.
What's New? While the effectiveness of systemic anticancer therapy is well documented, it commonly causes severe toxicity. This study of the 467 systemic anticancer therapy agents currently approved globally for clinical and/or research purposes found that peripheral neurotoxicity is associated with 45% of classical chemotherapies, 21% of targeted ...
Cassie Higgins   +3 more
wiley   +1 more source

Molecular and genomic advances in breast cancer: A comprehensive review of predictive and therapeutic innovations

open access: yesPrecision Medical Sciences, EarlyView.
Breast cancer subtypes, estrogen receptor‐positive (ER+), HER2‐enriched, and TNBC, are defined by genomic and epigenetic signatures. Multi‐omics profiling, immunotherapy, liquid biopsy, and AI‐driven radiogenomics enable precision medicine. Tools like Oncotype DX and PAM50 support personalized care.
Samina Malik   +4 more
wiley   +1 more source

Development of a novel cell-based assay system EPISSAY for screening epigenetic drugs and liposome formulated decitabine [PDF]

open access: yes, 2013
Extent: 11 p.BACKGROUND: Despite the potential of improving the delivery of epigenetic drugs, the subsequent assessment of changes in their epigenetic activity is largely dependent on the availability of a suitable and rapid screening bioassay.
Akkamsetty, Y.   +9 more
core   +2 more sources

The Functional Role and Molecular Characterization of the Therapeutic Target CLDN6 in Germ Cell Tumors

open access: yesAndrology, EarlyView.
ABSTRACT Background The tight junction protein CLDN6 has been identified as a cancer‐associated cell surface marker that is rarely expressed in healthy tissues. In testicular germ cell tumors (GCT), CLDN6 is particularly detectable in seminomas, embryonal carcinomas, and choriocarcinomas.
Jule Zwick   +7 more
wiley   +1 more source

Decitabine Increases the Transcription of RIG-I Gene to Suppress the Replication of Feline Calicivirus and Canine Influenza Virus

open access: yesMicroorganisms
Developing novel antiviral drugs has always been a significant forefront in biological medicine research. Antiviral drugs can be extracted, purified, and synthesized from various biological sources and by different methods.
Shaotang Ye   +7 more
doaj   +1 more source

Immunoprofiling, sex‐ and age‐related determinants of treatment response in paediatric, adolescent and young adult Hodgkin lymphoma

open access: yesBritish Journal of Haematology, EarlyView.
Multimodal integration of sex‐ and age‐related immune‐gene signatures with baseline tumor burden (TMTV1) improves prediction of treatment response in adolescents and young adults with classical Hodgkin lymphoma. Summary The study investigates how sex and age influence treatment response in paediatric, adolescent and young adult (AYA) classical Hodgkin ...
Valli De Re   +54 more
wiley   +1 more source

KMT2A degradation is observed in decitabine‐responsive acute lymphoblastic leukemia cells

open access: yesMolecular Oncology
Hypermethylation of tumor suppressor genes is a hallmark of leukemia. The hypomethylating agent decitabine covalently binds, and degrades DNA (cytosine‐5)‐methyltransferase 1 (DNMT1).
Luisa Brock   +10 more
doaj   +1 more source

Home - About - Disclaimer - Privacy